Intercept Pharma (ICPT) Misses Q4 EPS by 37c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. XYZ
8. CVS
9. SPY
10. SWKS

Go back to Intercept Pharma (ICPT) Misses Q4 EPS by 37c

Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Issues 2020 Operating Expense Guidance and Provides Business Update

February 25, 2020 7:00 AM EST

Worldwide Ocaliva net sales of $249.6 million for the full year 2019, representing 40% growth over the prior year

Our NDA was the first accepted by the FDA for liver fibrosis due to NASH

Completed enrollment of REVERSE, our Phase 3 study evaluating OCA for the treatment of compensated cirrhosis due to NASH

 Conference call scheduled for 8:30 a.m. ET today

NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company... More